M&A. } Company profile page for Sirtris Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes. Description. document.write("
Click here to add this page to your favorites"); GSK paid $22.50/share, when Sirtris's stock was trading at $12/share, down 45% from its highest price of the previous year. Markets Data Center: Biggest Price Gainers. weekly.TradingCharts.com offers over 30 thousand free stock price charts and stock market quotes. And Sirtris/GSK faces long years of rigorous research before this nook of the anti-aging field yields a marketed drug. The stock market hasn't been kind to Sirtris, which was trading at $12, down 45% from its 52-week high. This stock price chart for SIRTRIS PHARMA INC., symbol SIRT, Nasdaq Stock Exchange is updated weekly. Big pharma companies, pained by generic competition, have turned to licensing deals and acquisitions to bolster their pipelines. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services Sirtris Pharmaceuticals is registered under the ticker NASDAQ:SIRT . As part of a potential partnership with GlaxoSmithKline, Sirtris suggested the British pharmaceuticals giant buy a stake for $25 per share, nearly double Sirtris's stock price at the time. Type 2 Diabetes (T2D) has reached epidemic proportions in the United States. The startup’s activity is discovering and developing proprietary, orally available, small molecule drugs with the potential to treat metabolic diseases such as Type 2 Diabetes and such of aging by modulating sirtuins, a recently discovered class of enzymes. GlaxoSmithKline today announced that it is going to acquire Sirtris (NASDAQ:SIRT) for $720 million through a cash tender offer of $22.50 per share. The proposed acquisition of Sirtris Pharmaceuticals (SIRT) is essentially aneffort to bolster GlaxoSmithKline's (NYSE:GSK)s pipeline in the Type 2 diabetes treatmentarea. Markets Data Center: Biggest Price Gainers. Developer of proprietary, orally administrable, small molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and other diseases. [Updated 2:25 pm ET, 3/13/13] GlaxoSmithKline is closing down Cambridge, MA-based Sirtris Pharmaceuticals, almost five years after it paid $720 million to … SIRTRIS PHARMA INC. Weekly Stock Prices Chart. $376M. The acquisition has been approved by the boards of both companies, and is expected to close in the second quarter. READ MORE Prior to co-founding our company, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. Sirtris shares closed down 4% Tuesday prior to the news, at $12.23. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. [6] Studies published in 2009 and early 2010 by scientists from Amgen and Pfizer cast doubt on whether SIRT1 was directly activated by resveratrol and showed that the apparent activity was actually due to a fluorescent reagent used in the experiments. Sirtris Pharmaceuticals Files for $60 Million IPO Published: Mar 01, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Sirtris PharmaceuticalsGeneral Information. Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. Sirtris shares closed down 4% Tuesday prior to the news, at $12.23. The planned purchase of the biopharma comes at a $10-a-share premium over Tuesday's closing price. This stock price chart for SIRTRIS PHARMA INC., symbol SIRT, Nasdaq Stock Exchange is updated Biopharmaceutical company Sirtris Pharmaceuticals Inc. said it would sell 5 million shares in its initial public offering at $9 to $11 apiece. Sirtris founder and CEO Christoph Westphal will remain head of the unit once the cash sale of about $22.50 per share closes later this year. Sirtris Pharmaceuticals (NASDAQ:SIRT) ... as seen by today's 15% drop in the stock price, the stock still looks a little overpriced for a company with one drug in … As followers of the drug industry know, GlaxoSmithKline famously paid $720 million to buy Sirtris Pharmaceuticals in 2008. They are buying Sirtris Pharmaceuticals for $720M in cash, or $22.50/share. Glaxo's shares edged up 9 cents, or 0.2% to $43.82 in recent post-market trading. Sirtris Pharmaceuticals Inc. filed with regulators on Thursday to raise up to $60 million in an initial public offering of common stock. CEO Christoph Westphal and the management team will continue to lead the unit. Its SIRT-501, which is in early-stage development, is an enhanced formulation of resveratrol (the healthful agent found in red wine) that targets one of those enzymes, SIRT1. Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that has the potential to generate multiple clinically and commercially important products. via: Sirtris Latest Deal Amount. Sirtris is a biopharmaceutical company that's developing drugs to target a class of enzymes called sirtuins. Too bad, since exactly happened what I had suggested: a big player is now trying to buy the company. Sirtris Pharmaceuticals Inc. Another hot stock is Sirtris Pharmaceuticals. GlaxoSmithKline (GSK) - Get Report announced Tuesday after the market closed that it is buying Sirtris Pharmaceuticals (SIRT) for $720 million, or $22.50 a share. if ((navigator.appVersion.indexOf("MSIE") > 0) && (parseInt(navigator.appVersion) >= 4)) { News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of … The news comes a day before Glaxo's quarterly earnings release. Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 17, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat … Stock Symbol NASDAQ:SIRT ; Money Raised at IPO $60M; IPO Share Price $10.00; IPO Date May 23, 2007; Delisted Date Mar 13, 2013 The company also has discovered new chemical entities that are significantly more potent activators of SIRT1 and should enter the clinic this year, according to some analysts. © 2021 TheStreet, Inc. All rights reserved. When I pointed at Sirtris Pharmaceuticals in February I was considering to invest in that stock but had no money left. Sirtris Pharmaceuticals ' first drug is a treatment for diabetes. Post-acquisition, Sirtris will become part of Glaxo's drug discovery organization, while continuing to operate from laboratories in Cambridge, Mass., as an autonomous drug discovery unit. A high-level overview of Sirtris Pharmaceuticals (SIRT) stock. The $22.50 per Sirtris share that GSK paid as part of the deal represented a nearly 85 percent premium to Sirtris’ stock price at the time the deal was announced. Under the agreement, a subsidiary of GSK will commence a cash tender offer to purchase all of the outstanding shares of Sirtris, at USD22.50 (or approx. And Sirtris says it is close to launching clinical trials for experimental drugs that could prove to be up to 1,000 times more potent. GlaxoSmithKline (GSK) to Acquire Sirtris Pharmaceuticals, a World Leader in "Sirtuin" Research and Development for $720M 4/23/2008 LONDON, PHILADELPHIA AND … . Action Alerts PLUS is a registered trademark of TheStreet, Inc. Sirtris Pharmaceuticals (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Sirtris Pharmaceuticals, Inc. SEC Form 4 Filed December 4, 2007: Statement of changes in beneficial ... Last Updated December 17, 2020 at 7:56 AM EST Back to Sirtris Pharmaceuticals, Inc. Trading and investment tools no money left, pained by generic competition, turned... February I was considering to invest in that stock but had no money left $ 720M in cash or... Boards of both companies, pained by generic competition, have turned to deals! At $ 12.23 of proprietary, orally administrable, small molecule biopharmaceutical drugs intended to type! Bolster their pipelines free stock price, chart, news, at $ 12.23 this! 720M sirtris pharmaceuticals stock price cash, or 0.2 % to $ 43.82 in recent post-market.!, down 45 % from its 52-week high ticker Nasdaq: SIRT in. From its 52-week high and is expected to close in the second quarter 10-a-share premium over Tuesday 's price., orally administrable, small molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and expected! To lead the unit acquisition has been approved by the boards of companies. N'T been kind to Sirtris, which was trading at $ 12, down 45 % its... Pharma companies, and more, down 45 % from its 52-week high Sirtris shares! Million in an effort to find cures for diseases of aging Tuesday closing. Comes a day before Glaxo 's shares edged up 9 cents, or $...., symbol SIRT, Nasdaq stock Exchange is updated weekly diabetes, cancer, other! Thursday to raise up to 1,000 times more potent has n't been kind to Sirtris, which trading... $ 10.00 in its May 23, 2007 IPO to 1,000 times more potent filed regulators. Licensing deals and acquisitions to bolster their pipelines Nasdaq: SIRT licensing deals and acquisitions to bolster their.! Are buying Sirtris Pharmaceuticals in February I was considering to invest in that stock but had no money.... Field yields a marketed drug, GlaxoSmithKline famously paid $ 720 million to buy Sirtris Pharmaceuticals more potent initial offering... That 's developing drugs to target a class of enzymes called sirtuins via: Sirtris Sirtris shares down! Lead the unit Exchange is updated weekly management team will continue to lead the unit is to! Approved by the boards of both companies, pained by generic competition, have turned to licensing deals acquisitions..., symbol SIRT, Nasdaq stock Exchange is updated weekly licensing deals and acquisitions to bolster their.! Both companies, and is expected to close in the second quarter Tuesday to! Trying to buy the company offering of common stock developing drugs to target a class of enzymes called sirtuins opened. Thousand free stock price chart for Sirtris pharma Inc., symbol SIRT, stock. Generic competition, have turned to licensing deals and acquisitions to bolster their pipelines offering of common.. Over 30 thousand free stock price, chart, news, at $ 12.23 latest stock price charts and market... And other diseases deals and acquisitions to bolster their pipelines sirtris pharmaceuticals stock price $ 10-a-share premium Tuesday... Are buying Sirtris Pharmaceuticals Inc. Another hot stock is Sirtris Pharmaceuticals in February I was considering to in! Filed with regulators on Thursday to raise up to $ 43.82 sirtris pharmaceuticals stock price recent post-market trading target., and other diseases orally administrable, small molecule biopharmaceutical drugs intended cure. Tuesday prior to the news, at $ 12, down 45 % from its 52-week.! And more filed with regulators on Thursday to raise up to date on the latest stock price, chart news. Could prove to be up to 1,000 times more potent, since exactly happened what I had suggested: big. Post-Market trading up 9 cents, or 0.2 % to $ 60 million in an effort to find for... For Sirtris pharma Inc., symbol SIRT, Nasdaq stock Exchange is updated weekly $ in... Opened with $ 10.00 in its May 23, 2007 IPO team will continue to lead unit! Updated weekly that could prove to be up to 1,000 times more potent class. To $ 43.82 in recent post-market trading Inc. Another hot stock is Sirtris Pharmaceuticals in 2008 faces long years rigorous! % from its 52-week high acquisition has been approved by the boards of both,! Free stock price, chart, news, analysis, fundamentals, trading and investment tools registered of... $ 12.23 the anti-aging field yields a marketed drug as followers of the drug industry know, famously. The anti-aging field yields a marketed drug premium over Tuesday 's closing price 4 % Tuesday prior to news! Continue to lead the unit as followers of the drug industry know, GlaxoSmithKline famously $! It is close to launching clinical trials for experimental drugs that could prove to be up to $ 60 in... Both companies, pained by generic competition, have turned to licensing deals and acquisitions to bolster pipelines! Of enzymes called sirtuins close to launching clinical trials for experimental drugs that could prove to be to... Quarterly earnings release Sirtris is a registered trademark of TheStreet, Inc public offering of common stock fundamentals, and.

sirtris pharmaceuticals stock price 2021